OptimUM-09
Source
ESMO 2025 Butler et al.
Publications
PKC Inhibition in UM (darovasertib)
Darovasertib is a potential first-in-class oral, small-molecule inhibitor of PKC. It is being evaluated in multiple clinical trials in uveal melanoma, including in combination with crizotinib, an oral inhibitor of c-MET, in patients with metastatic disease and as an adjuvant therapy in the pre-metastatic setting. IDEAYA is also evaluating single-agent darovasertib as a neoadjuvant therapy in primary uveal melanoma.
PUMMA Study
Source
ASCO 2025 Kohja et al.
Updated analyses from a global meta-analysis in metastatic uveal melanoma (mUM) to determine progression free and overall survival benchmarks by line of therapy: An international rare cancers initiative (IRCI) ocular melanoma study
Read more (opens in a new tab)Phase 1 Study
Source
British Journal of Cancer 2023 Piperno-Neumann et al.
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Read more (opens in a new tab)NADOM Phase 2
Source
ASCO 2024 Joshua et al.
A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma
Read more (opens in a new tab)Phase 1 Case Study
Source
Ophthalmology Retina 2024 Hiong et al.
Globe salvage and vision preservation by neoadjuvant darovasertib and crizotinib in uveal melanoma
Read more (opens in a new tab)Phase 1 Case Study
Source
Oncogenesis 2024 Park et al.
PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma
Read more (opens in a new tab)Phase 1 Case Study
Source
Journal of Medicinal Chemistry 2024 Visser et al.
